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Viral etiologyon the etiologic role of viral infections, have been reported. The purpose of this study was
to assess microbiological differences according to initial site of care in patients with
community-acquired pneumonia.
Methods: We studied 496 patients 4 14 years of age collected from the study samples of
three population-based studies carried out in the same geographical area (‘‘Maresme’’
region in the Mediterranean coast in Barcelona, Spain) with the same methodology over an
8-year period (1987–1995).
Results: Fifty-six percent of patients were hospitalized and 44% were treated at home. Of
the 474 patients with etiological evaluation, 195 patients had an identifiable etiology
(overall diagnostic yield 41%). Streptococcus pneumoniae was the most common causative
organism. Viral infection was diagnosed in 26.5% of hospitalized patients vs. 13.2% of
ambulatory patients (P ¼ 0.03). Twenty-five percent of the 68 patients with documented
etiology treated at home had Chlamydia pneumoniae infection compared with 14.3% of
those treated in the hospital. Ten percent of hospitalized patients had pneumonia caused
by two pathogens compared with 9.7% of ambulatory patients. The association of viruses
and bacteria was the most frequent cause of dual infection (79% inpatients, 67%
outpatients).
Conclusions: This study has provided information on etiology of community-acquired
pneumonia in hospitalized patients and in patients treated at home. A considerable
proportion of patients had viral pneumonia, frequently requiring hospital admission for
inpatient care.
& 2007 Published by Elsevier Ltd.Introduction
Most etiologic studies of community-acquired pneumonia in
adults have been carried out in patients who were referred
to the hospital for consultation or in those hospitalized
for inpatient care. Little information is available on the
microbiologic etiology of outpatients with community-
acquired pneumonia. Moreover, a few population-based
studies assessing the etiology of pneumonia in both
hospitalized and ambulatory patients have been reported.
In some of these studies, however, respiratory viruses have
not been considered1 or it has been claimed that the
etiology of ambulatory community-acquired pneumonia
does not differ from that of severe pneumonia requiring
hospitalization.2 This study was designed to compare the
microbiological etiology of community-acquired pneumonia
according to initial site of care, whether outpatient or in-
hospital, with emphasis on the viral etiology, using data
from three population-based studies carried out in the same
geographical area with the same methodology over a 4-year
period.
Materials and methods
Study population
All subjects 414 years of age living in a pre-defined area of
the ‘‘Maresme’’ region in the Mediterranean coast in
Barcelona, Spain, with a definite diagnosis of community-
acquired pneumonia were included. These patients were
collected from the study samples of three population-based
studies carried out between November 1987 and November
1995.3–5 All physicians working in public primary health care
centers and private clinics of the ‘‘Maresme’’ region as wellas the emergency services of public and private reference
hospitals in the area participated in the reporting of cases.
All cases of clinically suspected community-acquired
pneumonia were prospectively registered. Criteria for
clinical suspicion of acute lower respiratory tract infection
included the presence of three or more of the following
manifestations: cough with or without sputum production,
dyspnea and/or wheezing, pleuritic chest pain or abdominal
pain, fever, headache, pneumonic consolidation on auscul-
tation of the chest, sweating, arthromyalgias, dysphagia,
and coryza. For clinically atypical community-acquired
pneumonia, one or more of the following criteria were
considered: sweating, arthromyalgias, dysphagia, and cor-
yza that required antibiotic prescription or persisted X5
days without antibiotics. In elderly patients, the possibility
of pneumonia was also considered in the presence of
prostration and/or anorexia and/or confusion or disorienta-
tion. In all cases in which criteria for clinical suspicion were
met, a chest radiograph was ordered. Patients with initial
doubtful radiographic images of community-acquired pneu-
monia were tentatively included in the study and then
excluded or definitively included according to clinical
evolution and subsequent roentgenographic findings. All
cases of community-acquired pneumonia were re-evaluated
by chest roentgenograms on the 5th day of illness and at
monthly intervals until complete recovery.
Patients with aspiration pneumonia (witnessed aspiration
with respiratory symptoms or oral content of aspiration) or
active pulmonary tuberculosis, and patients coming from
nursing homes or having been discharged from hospital at
least within 7 days before the onset of symptoms were
excluded.
Decisions about hospitalization were made according to
the risk classes defined by Fine et al.6 The pneumonia
severity index (PSI)7 was calculated in all hospitalized
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J. Almirall et al.2170patients with pneumonia. The PSI in patients attended in
the outpatient setting was not calculated due to unavail-
ability of biochemical results (serum glucose, blood urea
nitrogen, sodium) and hematocrit value.
For each individual population-based study, the Review
Board of the reference hospital approved the study
protocol. Informed consent was not obtained because no
special intervention for the purpose of the study was
performed and patients were treated according to standard
care of daily practice.Microbiological studies
In patients with fever X38 1C, two blood cultures were
drawn. When lower respiratory tract secretions (via fiber-
optic bronchoscopy, bronchoalveolar lavage, plugged double
catheter) or pleural fluid samples were obtained, these
were cultured too. Paired serology, at the moment of
diagnosis and within the 4–6th week were also collected.
Sera were tested for evidence of complement fixing
antibodies to influenza A and B; parainfluenza 1, 2, and 3;
adenovirus; respiratory syncytial virus (RSV); Chlamydia
psittaci; Coxiella burnetii, and Mycoplasma pneumoniae.
The indirect fluorescent antibody technique was used for
detecting immunoglobulin (IgG) against Legionella pneumo-
phila serogroups 1–6. The indirect microimmunofluores-
cence antibody technique was used for detecting IgG and
IgM against Chlamydia pneumoniae. When varicella pneu-
monia was suspected on the basis of clinical history and
typical cutaneous lesions consistent with chickenpox, test-
ing for antibodies was performed by standard complement-
fixation technique.
Urine samples were also collected and frozen at 30 1C to
perform the following tests in one batch towards the end of
the studies: test for pneumococcal polysaccharide capsular
antigen and Haemophilus influenzae type B capsular
antigen. In order to minimize possible non-specific reac-
tions, all urine samples were heated at 100 1C for 3min.
Urine samples were centrifuged at 2000 g for 10min and
tests for antigen were performed in both concentrated and
unconcentrated urine 20-fold by means of a disposable
ultrafilter (Minicon-B15 concentrator Amicon, Beverly, MA,
USA). H. influenzae type B capsular antigen was detected in
urine with a commercially available latex kit (Bactigen,
Wampole Laboratories, Cranbury, NJ, USA) according to the
manufacturer’s instructions. Pneumococcal polysaccharide
capsular antigen was detected in urine by counterimmu-
noelectrophoresis (CIE) with pneumococcal Omniserum
(Statens Serum Institut, Copenhagen, Denmark). In a
subgroup of the last study,5 urine samples were also tested
for L. pneumophila serogroup 1 antigen by ELISA.
Microbiological testing was always performed prior to the
administration of antibiotics. An etiologic diagnosis was
based on: (1) blood cultures yielding a bacterial or fungal
pathogen (in the absence of an apparent extrapulmonary
focus); (2) pleural fluid culture yielding a bacterial patho-
gen; (3) seroconversion, i.e., a four-fold rise in IgG-titers
for C. pneumoniae (IgGX1:512), M. pneumonia (IgGX1:80),
C. psittaci (IgG X1:64), L. pneumophila (IgG X1:128),
C. burnetii (IgG X1:80), respiratory viruses (influenza virus
A and B, parainfluenzavirus 1–3, RSV, adenovirus), and a four-fold rise in Varicella-zoster virus antibodies; (4) a positive
urinary antigen for Streptococcus pneumoniae polysaccharide
capsular antigen, H. influenzae type B capsular antigen, and
L. pneumophila serogroup 1 antigen; or (5) bronchoalveolar
lavage cultures yieldingX104 colony-forming units (CFU) per
milliliter, or protected specimen brush cultures yielding
X103 CFUmL1.
Results of sputum culture were not considered due to the
low yield of this technique8,9 and the controversy in the
interpretation of results as definite etiological agent of
community-acquired pneumonia.2,10,11Statistical analysis
The diagnostic yield of each microbiological technique was
expressed as the number of patients with a positive result
divided by the total number of patients submitted to the
diagnostic test. For the comparison of percentages, differ-
ences according to site of care were assessed with the Chi-
square (w2) test or the Fisher’s exact test. The Statistical
Package for the Social Sciences (SPSS, version 12.0) was used
for the analysis of data. Statistical significance was set at
Pp0.05.Results
In 86 (14.7%) of the 582 patients initially included in the
three population-based studies, the diagnosis of community-
acquired pneumonia was not confirmed (non-pneumonic
respiratory infection 36, pleural adhesions 10, lung cancer
13, atelectasis 13, acute pulmonary edema 7, lung abscess
4, chronic organized pneumonia 1, chronic vasculitis 1, and
extrinsic allergic alveolitis 1). Therefore, the study popula-
tion included 496 patients, 280 (56.5%) treated in the
hospital and 216 (43.5%) treated at home. The character-
istics of patients according to site of care are shown in
Table 1. The mortality rate was 6.4% for inpatients vs. 1.4%
for outpatients.
Of the 474 patients with etiological evaluation, 195
patients had an identifiable etiology, which resulted in an
overall diagnostic yield of 41.1%. A total of 215 pathogens
were identified, a single pathogen in 175 patients and two
pathogens in 20 (Table 2). S. pneumoniae was the most
common causative pathogen followed by C. pneumoniae and
M. pneumoniae.
Viral etiology (influenza A, influenza B, parainfluenza
virus, RSV, adenovirus, and varicella virus) was documented
in 48 patients (24.6%), 39 of whom were admitted to the
hospital and 9 were treated in the outpatient setting. In
hospitalized patients, viral etiology accounted for 16.8% of
all serological tests performed (39 out of 231), whereas in
ambulatory patients, viral etiology accounted for 4.8% of all
serological tests performed (9 out of 185). On the other
hand, viral etiology was documented as a single pathogen in
33 patients, or in association with other organisms in 15
patients (75% of dual infections). As shown in Table 2, the
diagnostic yield of invasive procedures with adequate
sampling was 100% followed by serological tests (31.3%),
pleural fluid culture (17.4%), urine antigen (13.5%), and
blood culture (7%).
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Table 1 Baseline characteristics of the study population by site of care.
Data Total (n ¼ 496) Inpatients (n ¼ 280) Outpatients (n ¼ 216)
Female sex, no. (%) 194 (39.1) 87 (31.1) 107 (49.6)
Age o65 years, no. (%) 338 (68.1) 150 (53.6) 188 (87.0)
Age X65 years, no. (%) 158 (31.9) 130 (46.4) 28 (13.0)
Co-morbidity, no. (%)
None 393 (79.2) 204 (72.9) 189 (87.5)
One underlying illness 58 (11.7) 41 (14.6) 17 (7.9)
Two underlying illnesses 45 (9.1) 35 (12.5) 10 (4.6)
Respiratory rate, mean (SD) 23 (8) 26 (8) 19 (4)
Temperature, (1C) mean (SD) 38 (1.0) 38.2 (0.9) 37.7 (0.9)
Multilobar pneumonia, no. (%) 29 (5.8) 28 (10) 1 (0.5)
Bilateral pneumonia, no. (%) 22 (4.4) 21 (7.5) 1 (0.5)
Pleural effusion, no. (%) 39 (7.9) 38 (13.6) 1 (0.5)
Pneumonia severity index, no. (%)
Class I 33 (11.8)
Class II 64 (22.8)
Class III 66 (23.6)
Class IV 80 (28.6)
Class V 37 (13.2)
SD: standard deviation.
Diabetes mellitus, heart failure, bronchial asthma, chronic obstructive pulmonary disease, chronic bronchitis, epilepsy, Parkinson’s
disease, neuromuscular diseases, swallowing disorders, dementia, chronic liver dysfunction, chronic renal insufficiency, cancer in
remission.
Etiology of community-acquired pneumonia 2171In the group of 280 inpatients, an etiologic diagnosis was
made in 133 (47.5%), with a total of 147 pathogens
identified. In the group of 216 outpatients, 62 (28.7%) had
an identifiable etiology, with a total of 68 pathogens
identified. Diagnostic techniques were different according
to the site of care. As expected, culture of respiratory
samples obtained by invasive procedures was only per-
formed in hospitalized patients with a 100% diagnostic yield.
Urine antigen testing and serological tests were performed
more frequently among hospitalized patients, but differ-
ences compared with outpatient care were not statistically
significant. Blood cultures were more often performed in the
inpatient care than in the outpatient care setting (8.6% vs.
1.4%, Po0.0001). Diagnostic yield was consistently higher
among inpatients than ambulatory patients for serological
tests (35.5% vs. 25.9%, P ¼ 0.04), blood cultures (9.7% vs.
2.2%, P ¼ 0.0006), and urine antigens (16.7% vs. 9.6%,
P ¼ 0.04) (Table 2).
Table 3 shows the etiology of community-acquired
pneumonia according to site of care. In both groups,
S. pneumoniae was the most common causative organism.
Viral infection was diagnosed in 26.5% of hospitalized
patients compared with 13.2% of ambulatory patients
(P ¼ 0.03). There were no differences in the distribution
of patients with viral pneumonia according to PSI classes
(I–II, 23.3%; III, 20.8%; IV–V, 19.5%). On the other hand, the
same distribution of cases of viral pneumonia was observed
along the three study periods surveyed and no predominant
seasonal distribution was recorded. Twenty-five percent of
the 68 patients with documented etiology treated at home
had C. pneumoniae infection compared with 14.3% of those
treated in the hospital. M. pneumoniae and C. burnetii weremore frequently identified in ambulatory patients. Pneumo-
nia cause by Pneumocystis jiroveci was only documented in
the hospitalized group.
A total of 10.5% of hospitalized patients had community-
acquired pneumonia caused by two pathogens compared
with 9.7% of patients treated at home. The most commonly
involved pathogens in dual infections among hospitalized
patients were viruses (n ¼ 11), S. pneumoniae (n ¼ 7), and
C. pneumoniae (n ¼ 6). Viruses were identified in four
ambulatory patients with community-acquired pneumonia
caused by two pathogens, S. pneumoniae in three, and
C. pneumoniae in three. The association of viruses and
bacteria was the most frequent cause of dual infection
(78.6% inpatients vs. 66.7% outpatients).Discussion
Following pre-established criteria, 57.1% of patients were
admitted to the hospital. There is a large variability
across studies in relation to differences in strategies for
admission decision, and a tendency to overestimate the
severity of pneumonia.12 In our group of hospitalized
patients, 34.6% belonged to PSI risk classes I and II, which
is similar to the 31.1% reported in a multicenter study
carried out in our country.13 Diagnostic yield was low,
although consistent with data of other studies using
similar procedures.14 Higher yield has been reported
in studies that have included pathogens identified in
sputum samples.15,16 When diagnostic yield according to
the different procedures was assessed, results were con-
sistently higher among inpatients than ambulatory patients.
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Table 2 Distribution of the 215 causative pathogens of community-acquired pneumonia in 195 patients by diagnostic tests.
Pathogen No. of
pathogens
Serological
tests
Blood
culture
Pleural fluid
culture
Urine
antigen
BAS, BAL, or PDC
Streptococcus
pneumoniae
62 23/384 2/23 49/393
Chlamydia pneumoniae 38 38/274
Mycoplasma pneumoniae 25 25/416
Influenza A 14 14/416
Pneumocystis jiroveci 13 13/14
Legionella pneumophila 10 10/416 1/30
Parainfluenza virus 10 10/416
Coxiella burnetii 8 8/416
Respiratory syncytial virus 7 7/416
Influenza B 7 7/416
Adenovirus 7 7/416
Varicella-zoster virus 3 3/3
Haemophilus influenzae 3 3/393
Serratia marsescens 1 1/384
Pseudomonas aeruginosa 1 1/384
Streptococcus milleri 1 1/23
Streptococcus pyogenes 1 1/384
Brucella 1 1/384
Chlamydia psittaci 1 1/416
Streptococcus sanguis 1 1/23
Bordetella bronchiseptica 1 1/14
Total 215 130/416 27/384 4/23 53/393 14/14
Diagnostic yield (%) 31.3 7.0 17.4 13.5 100
Site of care
Inpatients, n ¼ 280 147 82/231 24/248 4/23 36/216 14/14
Diagnostic yield (%) 35.5 9.7 17.4 16.7 100
Outpatients, n ¼ 216 68 48/185 3/136 17/177
Diagnostic yield (%) 25.9 2.2 9.6
Results are expressed as number of patients with positive results/total number of patients submitted to the diagnostic test; BAS:
selective bronchoaspiration; BAL: bronchoalveolar lavage; PDC: plugged double catheter. Dual pathogens were observed in 20 patients:
Streptococcus pneumoniae in association with influenza A virus (n ¼ 4), Mycoplasma pneumoniae (n ¼ 2), Chlamydia pneumoniae
(n ¼ 1), respiratory syncytial virus (n ¼ 1), parainfluenza virus (n ¼ 1), and adenovirus (n ¼ 1); Chlamydia pneumoniae in association
with adenovirus (n ¼ 4), parainfluenza virus (n ¼ 2), Legionella pneumophilae (n ¼ 1), and respiratory syncytial virus (n ¼ 1); Coxiella
burnetii and influenza A virus (n ¼ 1); and Pneumocistis jiroveci and Bordetella bronchiseptica (n ¼ 1).
J. Almirall et al.2172The relationship between greater yield and severity of
pneumonia has been already reported.16,17
S. pneumoniae was the most common pathogen in either
inpatients or outpatients, which is in agreement with other
studies.18 Viruses were the second most frequent causative
agents. Although in studies in immunocompromised patients
in whom herpes simplex virus was documented in 42% of
cases and cytomegalovirus in 31%,19 in non-immunocompro-
mised patients with community-acquired pneumonia, viral
etiology as single or associated infection has been observed
in 18–20% of patients admitted to the hospital.20,21 As single
causative agent, viral infection has been recorded in 9% of
hospitalized patients.20 In the present study, viral pneumo-
nia was associated with a higher severity of illness. It was
diagnosed in 26.5% of patients admitted to the hospital,
18.3% as single pathogen, whereas in patients treated at
home these percentages were 14.5% and 8.1%, respectively.Similar findings were reported by Lagerstro¨m et al.22 with
viral infection detected in 13.9% of ambulatory patients
(single pathogen 33.3%, dual pathogen 66.7%). The inclusion
of paired serological test in the diagnostic protocol may
account for the high percentage of viral pneumonia
observed in the present study. In fact, paired serological
tests were performed in 231 of 280 inpatients and in 185 of
216 outpatients. Although these data do not possibly reflect
routine daily practice, they are indicative of the role played
by major respiratory viruses in the etiology of community-
acquired pneumonia, which can be confirmed by the use
of new diagnostic techniques of rapid viral detection, such
as real-time polymerase chain reaction (PCR).23,24 The
etiological role of viral infections in adult lower respiratory
tract infection in the outpatient setting has been high-
lighted in a recent study,25 in which viruses accounted for
63% of infections with rhinoviruses being the most common
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Table 3 Distribution of pathogens of community-acquired pneumonia by place of care.
Pathogen Inpatients (n ¼ 280) Outpatients (n ¼ 216) P-value
Streptococcus pneumoniae 44 (29.9) 18 (26.5) 0.6
Viruses 39 (26.5) 9 (13.2) 0.03
Chlamydia pneumoniae 21 (14.3) 17 (25.0) 0.08
Mycoplasma pneumoniae 13 (8.8) 12 (17.6) 0.07
Pneumocystis jiroveci 13 (8.8) 0 0.01
Legionella pneumophila 7 (4.8) 3 (4.4) 1.0
Coxiella burnetii 1 (0.7) 7 (10.3) 0.002
Haemophilus influenzae 1 (0.7) 2 (2.9) 0.2
Serratia marcescens 1 (0.7) 0 1.0
Pseudomonas aeruginosa 1 (0.7) 0 1.0
Streptococcus milleri 1 (0.7) 0 1.0
Streptococcus pyogenes 1 (0.7) 0 1.0
Brucella spp. 1 (0.7) 0 1.0
Chlamydia psittaci 1 (0.7) 0 1.0
Streptococcus sanguis 1 (0.7) 0 1.0
Bordetella bronchiseptica 1 (0.7) 0 1.0
Total 147 (100) 68 (100)
Percentages in parentheses.
Etiology of community-acquired pneumonia 2173organisms. In this study, however, the diagnostic methodol-
ogy was different from the current study. The authors
employed PCR and reverse PCR technology and also sputum
samples. In our study, the three patients with clinical
manifestations suggestive of varicella were hospitalized and
the etiological diagnosis was confirmed by serological test.
Cases of mild community-acquired pneumonia caused by
Varicella-zoster virus and treated at home are probably
underdiagnosed if patients with this condition are not
submitted to other diagnostic studies.
C. pneumoniae was the third more frequent etiologic
agent among inpatients and the second most frequent
pathogen among ambulatory patients. Interestingly, seven
of eight patients with C. burnetii infection were treated as
outpatients. C. burnetii is a relatively common cause of
community-acquired pneumonia in some geographical areas
and among people in contact with animals.26,27 Infection by
L. pneumophila is uncommon in the community in the
absence of outbreaks.28 However, L. pneumophila was the
cause of community-acquired pneumonia in 4.1% of cases
and despite the fact that this organism has been implicated
with a greater severity of illness,1 in our study, 30% of
patients were treated at home, which is consistent with the
data reported by Carratala` et al.14 Likewise, patients with
M. pneumoniae were preferentially treated as outpatients.2
H. influenzae is a common etiology of community-acquired
pneumonia in elderly patients and in patients with chronic
obstructive pulmonary disease,29 but in the present study
the diagnostic yield was low because results of sputum
culture were not considered.
In this study, 10.4% of patients with etiological diagnosis
had two pathogens identified. In 75% of these cases a viral
agent was detected, which probably was the cause of
bacterial superinfection. In agreement with the study of De
Roux et al.,20 viral agents in patients with dual infection
occurred in association with S. pneumoniae or C. pneumo-niae. Community-acquired pneumonia with more than one
organism recovered is a challenging dilemma30 because it is
difficult to assess the role of individual organisms in the
pathogenesis of the disease. In some cases, the presence of
both pathogens may contribute to the illness, although in
other cases, infection by one pathogen may favor the second
pathogen to be the cause of community-acquired pneumo-
nia. Other studies have shown dual pathogens in 10–25% of
cases, probably in relation to the diagnostic procedures
used.31 In contrast, other authors considered that commu-
nity-acquired pneumonia is caused by a single pathogen, the
remaining organisms isolated representing colonization of
the airways, and attributing co-infection to punctual cases,
such as aspiration pneumonia or lung abscesses caused by
anaerobes.2
In a recent study covering the period from 1996 to 200132
assessing the incidence and principal microbial patterns of
mixed community-acquired pneumonia in a Barcelona
teaching hospital, the most frequent combination was
S. pneumoniae and H. influenzae followed by influenza
virus A and S. pneumoniae. In our study, the most commonly
involved pathogens in dual infections among hospitalized
patients were also viruses, S. pneumoniae and C. pneumo-
niae. In a 2-year prospective study of consecutive patients
with community-acquired pneumonia carried out in Alicante
(Spain),33 a single pathogen was detected in 45% cases and
two or more pathogens in 5.7% cases. Mixed infections were
seen across all age groups and in patients treated both in
hospital and as outpatients. The most frequent combina-
tions of pathogens were those of a bacterium plus an
‘‘atypical’’ organism (28.6%) and of two bacterial organisms
(28.6%). Patients with mixed pneumonia were more likely to
have underlying medical conditions, and they may have a
more severe course of disease.
Finally, the limitation of the method used to detect
pneumococcal antigen in urine should be recognized. Novel
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technique for detecting urinary S. pneumoniae antigen in
the etiologic diagnosis of community-acquired pneumonias
have been recently introduced. In a prospective study of 959
inpatients with community-acquired pneumonia in which
urinary pneumococcal antigen content was determined in
911 using the immunochromatography assay, the percentage
of diagnoses of pneumococcal pneumonias increased by 26%,
while the overall etiologic diagnosis increased from 28% to
49% compared with conventional microbiologic methods.34
The technique sensitivity was 81%; the specificity oscillated
between 80% in community-acquired pneumonia with non-
pneumococcal etiology and 99% for patients with fractures
without infections. Determination of urine pneumococcal
antigen is a rapid, simple analysis with good sensitivity and
specificity, which increased the percentage of etiologic
diagnoses.
This study in which data provided come from three
previous studies conducted from 1987 to 1995 has provided
information on etiology of community-acquired pneumonia
in hospitalized patients and in patients treated at home
using population-based data from studies in a single region
of Spain. A considerable proportion of patients had viral
pneumonia, frequently requiring hospital admission for
inpatient care.
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